Obesity and insulin resistance enjoy a complex relationship that gives rise to a range of metabolic disorders, including type 2 diabetes, dyslipidemia and coagulation disorders. Teasing apart this relationship could yield new therapies to treat some of these conditions and two new reports point to the adipocyte-secreted protein, adiponectin, as a new molecular target. (pages 941–946 and pages 947–953)
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Endocrine, genetic, and microbiome nexus of obesity and potential role of postbiotics: a narrative review
Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity Open Access 20 October 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Renee Lucas
References
Spiegelman, B.M. & Flier, J.S. Obesity and the regulation of energy balance. Cell 104, 531–543 (2001).
Saltiel, A.R. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104, 517–529 (2001).
Berg, A.H., Combs, T.P., Du, X., Brownlee, M. & Scherer, P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Med. 7, 947–953 (2001).
Yamauchi, T. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med. 7, 941–946 (2001).
Scherer, P.E., Williams, S., Fogliano, M., Baldini, G. & Lodish, H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 270, 26746–26749 (1995).
Hu, E., Liang, P. & Spiegelman, B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 271, 10697–10703. (1996).
Fruebis, J. et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. USA 98, 2005–2010 (2001).
Kahn, B.B. & Flier, J.S. Obesity and insulin resistance. J. Clin. Invest. 106, 473–481 (2000).
Olefsky, J.M. & Saltiel, A.R. PPARγ and the treatment of insulin resistance. Trends Endocrinol. Metab. 11, 362–368 (2000).
Shulman, G.I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106, 171–176 (2000).
Kissebah, A.H. et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc. Natl. Acad. Sci. USA 97, 14478–14483 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Saltiel, A. You are what you secrete. Nat Med 7, 887–888 (2001). https://doi.org/10.1038/90911
Issue Date:
DOI: https://doi.org/10.1038/90911
This article is cited by
-
Endocrine, genetic, and microbiome nexus of obesity and potential role of postbiotics: a narrative review
Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity (2023)
-
Developmental Origins of Obesity: Programmed Adipogenesis
Current Diabetes Reports (2013)
-
Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases
Nature Reviews Drug Discovery (2010)
-
A Polymorphism at the IL6ST (gp130) Locus Is Associated With Traits of the Metabolic Syndrome
Obesity (2008)
-
A Visfatin Promoter Polymorphism Is Associated with Low‐Grade Inflammation and Type 2 Diabetes
Obesity (2006)
